EGFR and non-small cell lung carcinoma: Anti-angiogenic therapy, targeting the vascular endothelial growth factor (VEGF) signaling pathway, has shown efficacy in combination with platinum-doublet chemotherapy in advanced NSCLC without a driver alteration, and with EGFR TKI in advanced EGFR mutated NSCLC [11].